Sesame Summit 2026 – application open

10 Medtech Startups to watch in 2021 – Selected

The global medtech market was projected to reach US$ 481.2 billion in 2020. Continuing it’s growth at a CAGR of 5.2% during 2021-2026 it is projected to reach US$ 652.3 billion by 2026.

The largest medtech market is North America with a market share of around 43% in 2018.

Europe follows in second place and makes up 27% of the world market. The biggest markets in Europe are Germany, France, the United Kingdom, Italy and Spain.

Here are 10 Medtech Startups to Watch in 2021.


Lalibela Global-Networks

Country: Ethiopia

Year: 2016

Funding Stage: (Information unavailable)

Investors: (Information unavailable)

Description: Lalibela Global-Networks aims to lead the digital transformation of the health sector in Africa. The startup offers healthcare software, including a digital health record system: ABAY-CHR to automate hospital management and reduce day-to-day stationery resources.

Streamlining administrative tasks and reducing time spent finding patient files, Lalibela Global-Networks improves the functionality of medical centers while making healthcare more affordable for patients.

Highlight: Lalibela Global-Networks was the winner of Web Summit’s PITCH startup competition 2020.


XUND

Country: Austria

Year: 2018

Funding Stage: Seed

Investors: TBA Tyrolean Business Angel

Description: XUND is a Vienna based digital health startup developing an AI-powered health assistant designed to improve the quality and accessibility of healthcare. By providing a digital interface between users and the healthcare system, XUND aims to save time, costs and increase the quality of life.

Highlight: PITCH quarter-finalist at Web Summit 2020


Smart Diagnosis

Country: South Korea

Year: 2018

Funding Stage: Early-Stage

Investors: (Information unavailable)

Description: Smart Diagnosis has developed a vital signs extraction algorithm that can analyse the human eye using a smartphone camera for a full patient health assessment.

The Smart Diagnosis app will be accessible on any mobile device anywhere in the world and will also be integrable with other digital healthcare systems.

Highlight: PITCH quarter-finalist at Web Summit 2020


Geneonbiotech

Country: South Korea

Year: (Information unavailable)

Funding Stage: Early-Stage

Investors: (Information unavailable)

Description: Geneonbiotech offers a simple, non-invasive Covid-19 diagnostic solution that greatly reduces time taken to produce a result.

Users provide a saliva sample, rather than a nasal scraping, and are given a result within 45 minutes. Test results are 99 percent accurate, and the system can be used by non-experts.

Geneonbiotech’s testing platform also incorporates a telemedicine communication service to help improve diagnostics and user care.

Highlight: PITCH quarter-finalist at Web Summit 2020


AiDx Medical

Country: Netherlands

Year: 2019

Funding Stage: Pre-Seed

Investors: EIT Health Headstart Fund

Description: AiDx technology brings an affordable alternative to standard microscopic examination by optimally addressing all components of the diagnostic cycle.

Highlight: Winner of Digital Health & Medical Devices category at Hello Tomorrow Summit 2020


TeleMedC

Country: Singapore

Year: 2014

Funding Stage: Early-Stage

Investors: (Information unavailable)

Description: TeleMedC is a diagnostic imaging solutions company using sophisticated retinal imaging.

Their primary objective is to provide low cost diagnostic solutions for point-of-care screening and virtual management of eye and chronic diseases throughout the world.

Highlight: Finalist in Digital Health & Medical Devices at Hello Tomorrow Summit 2020 & ‘Most Investable Startup’ award at Slingshot – Startup Competition of SWITCH 2020


Vibrosonic GmbH

Country: Germany

Year: 2016

Funding Stage: Grant Funding

Investors: EASME – EU Executive Agency for SMEs

Description: Vibrosonic has developed a hearing contact lens which is designed to mimic the natural hearing process to a large extent and thus significantly improve the sound experience of hearing impaired people.

Highlight: Finalist in Digital Health & Medical Devices at Hello Tomorrow Summit 2020 & Spin-off of from the Fraunhofer Project Group


Cirqle Biomedical

Country: Denmark

Year: 2018

Funding Stage: Pre-Seed

Investors: BioInnovation Institute & Rhia Ventures

Description: Circle Devices develops a next generation contraceptive product, which aims to create a natural, desirable and safe alternative to existing contraceptive products.

Highlight: Finalists in Digital Health & Medical Devices at Hello Tomorrow Summit 2020


Nanosynex

Country: Israel

Year: 2017

Funding Stage: Grant Funding

Investors: EASME – EU Executive Agency for SMEs & MassChallenge

Description: Nanosynex is developing a diagnostic test that can check bacterial resistance to antibiotics in a record time using microfluidics techniques, based on a revolutionary scientific development from the Technion.

The test will help doctors determine the most appropriate antibiotic treatment for patients and provide same day results. Same day results will help reduce the spread of resistant bacteria in an environment and significantly lower the burden on healthcare costs.

Highlight: Finalists in Digital Health & Medical Devices at Hello Tomorrow Summit 2020


Cellsway

Country: UK & Turkey

Year: 2020

Funding Stage: Pre-Seed

Investors: (Information unavailable)

Description: Cellsway focuses on the development of microfludics and lab-on-a-chip systems for biomedical applications.

The core product of the company is a liquid biopsy platform which uses a simple blood sample for cancer diagnostics and cancer research.

The patent-pending microfluidic technology enables isolation and enumeration of Circulating Tumor Cells from the blood samples of cancer patients.

Highlight: Finalists in Digital Health & Medical Devices at Hello Tomorrow Summit 2020


Medicsen

Country: Spain

Year: 2015

Funding Stage: Seed

Investors: dotforge, TURN8, Vertical.vc, EASME – EU Executive Agency for SMEs & Hot DesQ

Description: MedicSen’s aim is to launch a treatment that will change the way we deal with diabetes forever.

They have created an application capable of integrating information from continuous glucose meters with other parameters introduced by the user or collected by intelligent devices. The end results offers users a record of their glycemic values and provides a reliable prediction of future values.

MedicSen uses an innovative learning algorithm that communicates with the user through a chat-bot type interface.

Highlight: Winner of Pitch Competition at EU-Startups Summit 2018 & Track Winner of ‘Health & Wellbeing’ at South Summit Competition 2020


If you’ve found this report valuable and if you’re a corporate or investor looking for innovative startups within a specific market, please get in touch.

you might also like

Fundraising 1 day ago

European impact investing is gaining unprecedented momentum as institutional capital increasingly demands measurable social and environmental returns alongside financial performance. This shift has created fertile ground for specialised funds that can navigate the complex intersection of profit and purpose, particularly as EU regulations like the Sustainable Finance Disclosure Regulation reshape the investment landscape. Rubio Impact Ventures has successfully closed its third fund at €70 million, reinforcing its distinctive approach of tying 100% of investments to measurable impact outcomes. The Madrid-based venture capital firm has established itself as a leading voice in European impact investing, demonstrating that rigorous impact measurement and strong financial returns need not be mutually exclusive. Impact investing fund closure signals sector maturation The successful closure of Rubio’s third fund reflects growing investor appetite for impact-focused strategies across Europe. Unlike traditional ESG approaches that often apply impact considerations as an overlay, Rubio’s methodology embeds impact measurement into every investment decision from day one. This comprehensive approach resonates particularly well with European institutional investors who face increasing regulatory pressure to demonstrate genuine sustainability credentials. The fund’s investor base comprises a mix of family offices, institutional investors, and impact-focused limited partners across Europe, highlighting the broadening appeal of impact investing beyond traditional philanthropic circles. Rubio’s track record of delivering both measurable impact and competitive financial returns has enabled it to attract capital from investors who previously viewed impact investing as requiring financial trade-offs. “Our third fund represents not just capital, but a mandate to prove that impact and returns are complementary forces,” explains the fund’s investment team. “European startups are uniquely positioned to lead global impact innovation, particularly in areas where regulatory frameworks create competitive advantages.” European impact startups attract focused capital Rubio’s investment thesis centres on European startups addressing sustainability challenges through technology-driven solutions. The firm’s portfolio spans sectors including clean technology, circular economy, social impact, and sustainable agriculture—areas where European companies often benefit from supportive regulatory environments and sophisticated consumer demand for sustainable alternatives. The €70 million fund size positions Rubio to lead Series A and B rounds for European impact startups, a critical funding gap in the market. Many impact-focused companies struggle to scale beyond seed funding, as traditional venture capital firms often lack the specialised expertise to evaluate impact metrics alongside financial projections. Rubio’s dedicated approach addresses this market inefficiency directly. The fund’s 100% impact-tied investment approach requires portfolio companies to establish clear, measurable impact objectives that align with UN Sustainable Development Goals. This methodology provides both entrepreneurs and investors with concrete frameworks for tracking progress beyond traditional financial metrics, creating accountability structures that drive genuine impact outcomes. This successful fund closure signals growing maturation within European impact investing, where specialised capital increasingly flows to startups that can demonstrate both scalable business models and measurable positive impact. As European markets continue prioritising sustainability across all sectors, focused impact funds like Rubio’s third vehicle are becoming essential infrastructure for the continent’s transition to a more sustainable economy.

Fundraising 1 day ago

Impact measurement in European business is shifting from optional add-on to strategic necessity. As sustainability regulations tighten across the EU and stakeholder capitalism gains momentum, startups building the infrastructure for measurable impact are attracting serious attention. Contribe exemplifies this trend, having just secured €1.3 million in pre-seed funding to accelerate its impact measurement platform across European markets. The funding round positions Contribe at the intersection of two powerful European movements: the regulatory push for transparent impact reporting and the growing demand from investors for quantifiable sustainability metrics. Pre-seed funding round attracts impact-focused investors While the specific investors in Contribe’s €1.3 million pre-seed round remain undisclosed, the funding reflects a broader European appetite for impact measurement solutions. European VCs are increasingly prioritising startups that can quantify and optimise social and environmental outcomes, particularly as EU regulations like the Corporate Sustainability Reporting Directive (CSRD) create compliance requirements. The pre-seed timing suggests Contribe is positioning itself ahead of the regulatory curve. With CSRD requirements rolling out progressively through 2026, companies across Europe will need robust impact measurement systems. This regulatory tailwind creates a compelling investment thesis for early-stage funds focused on regulatory technology and sustainability infrastructure. Impact-focused investors are drawn to platforms that can standardise measurement across diverse sectors and geographies – a particular challenge in Europe’s fragmented market landscape. The funding will likely support Contribe’s efforts to build scalable measurement frameworks that work across different European regulatory environments. Impact platform targets European compliance landscape Contribe’s platform addresses a critical gap in European impact measurement infrastructure. While traditional metrics focus on financial returns, Contribe enables organisations to quantify social and environmental outcomes using standardised methodologies. This capability becomes increasingly valuable as European businesses face mounting pressure to demonstrate measurable impact alongside profitability. The platform’s approach aligns with European preferences for collaborative, stakeholder-driven business models rather than purely profit-maximising approaches. By providing transparent measurement tools, Contribe supports the broader European vision of sustainable capitalism that balances multiple bottom lines. The €1.3 million funding will likely focus on product development and market expansion across key European markets. Given the diverse regulatory requirements across EU member states, Contribe must build flexibility into its platform while maintaining standardisation – a complex technical and commercial challenge that could determine its competitive position. European organisations increasingly require impact measurement solutions that integrate with existing business processes rather than operating as standalone systems. This integration challenge represents both an opportunity and a technical hurdle for platforms like Contribe. The pre-seed funding signals confidence in Contribe’s ability to navigate Europe’s complex impact measurement landscape. As regulatory requirements intensify and stakeholder expectations evolve, platforms that can deliver accurate, standardised impact measurement will become essential infrastructure for European business.

Fundraising 1 day ago

The European venture capital landscape is witnessing a fascinating counter-trend. While many funds chase consensus picks and proven business models, a growing number of investors are deliberately seeking the outliers—the companies that don’t fit neat categories or follow traditional playbooks. This contrarian approach has found its latest expression in Amsterdam. henQ, the Dutch venture capital firm, has successfully closed its latest fund at €67.57 million, specifically targeting what they call “the odd ones out”—unconventional startups that other investors might overlook. The fund represents a bold statement in an increasingly homogenised venture landscape, where pattern recognition often trumps genuine innovation. For European founders building something truly different, this couldn’t come at a better time. The continent’s startup ecosystem has matured significantly, but with that maturity has come a certain conservatism amongst investors. henQ’s approach offers a refreshing alternative for entrepreneurs whose ventures don’t tick the usual boxes. Venture fund strategy targets overlooked opportunities henQ’s investment thesis centres on a fundamental belief that the most interesting opportunities often lie where others aren’t looking. The Dutch VC has built its reputation by backing companies that challenge conventional wisdom—startups that might be too early, too niche, or simply too unconventional for traditional funds. The €67.57 million fund positions henQ to make meaningful investments in companies across Europe, with particular focus on early-stage ventures that demonstrate genuine innovation rather than incremental improvements. Unlike many European VCs who increasingly mimic Silicon Valley investment patterns, henQ deliberately charts its own course. “We’re not interested in the obvious deals,” explains the fund’s approach to portfolio construction. “Our sweet spot is finding exceptional founders who are solving problems in ways that others dismiss as too risky or too different. These are often the investments that generate the most significant returns.” The fund’s strategy resonates particularly well within the Dutch tech ecosystem, where pragmatism and innovation have long coexisted. Amsterdam’s startup scene has produced numerous success stories by taking unconventional approaches to traditional problems, from Adyen’s unique payment processing architecture to Booking.com’s contrarian travel booking model. European market positioning and investment focus The timing of henQ’s fund closure reflects broader shifts in European venture capital. As the market has become more competitive, funds are increasingly differentiating themselves through specialized investment theses rather than generalist approaches. henQ’s focus on unconventional startups represents a calculated bet that the next wave of European unicorns will emerge from unexpected directions. The fund’s European focus is particularly strategic given the continent’s regulatory environment. EU frameworks like GDPR and the upcoming AI Act often favour companies that build privacy and compliance into their core architecture from day one—precisely the kind of foundational thinking that characterises henQ’s target investments. With this new fund, henQ can back companies across their growth journey, from pre-seed through Series A stages. The approach allows them to maintain conviction in their portfolio companies even when other investors might hesitate to follow on. This patient capital approach aligns well with European startup timelines, which often require longer development cycles than their US counterparts. The €67.57 million fund signals confidence in Europe’s capacity to generate genuine innovation beyond the well-trodden paths of fintech and SaaS. For European entrepreneurs building something genuinely different, henQ’s contrarian approach offers both capital and validation that unconventional thinking still has a place in venture capital.

Subscribe to
our Newsletter!

Stay at the forefront with our curated guide to the best upcoming Tech events.